Asthma Treatment Standard Set

The Cayman Asthma Treatment Standard Set contains three potent, selective Cysteinyl Leukotriene (CysLT) 1 receptor antagonists (10 mg each) currently used clinically for the treatment of asthma. Zafirlukast and Montelukast (sodium salt), sold under the trade names Accolate and Singulair, respectively, are used for the treatment of asthma as well as for the symptoms associated with allergic rhinitis. Pranlukast, sold under the trade name Ultair, was the first CysLT receptor antagonist marketed for the treatment of asthma. In addition to these three CysLT1 receptor antagonists, the asthma pak also includes Zileuton, which is supplied free of charge. Zileuton is a reversible 5-LO inhibitor that was approved in 1997 for the prevention and treatment of asthma in the USA, but was withdrawn by Abbott Laboratories in 2003.